岡山医学会雑誌
Online ISSN : 1882-4528
Print ISSN : 0030-1558
症例報告
インフリキシマブが著効した免疫関連有害事象大腸炎の1例
岩室 雅也平岡 佐規子大塚 基之
著者情報
ジャーナル 認証あり

2024 年 136 巻 2 号 p. 69-73

詳細
抄録
 A 52-year-old Japanese man diagnosed with non-small cell lung cancer initiated chemotherapy with tremelimumab, durvalumab, nanoparticle albumin-bound paclitaxel, and carboplatin. On the fourth day of the first treatment course, he developed a fever, followed by watery diarrhea exceeding 10 episodes per day and bloody stools the next day. Immunotherapy-related adverse event colitis was diagnosed through CT scans and colonoscopy examinations. Despite the ineffectiveness of systemic steroid administration, prompt alleviation of symptoms was achieved through the administration of infliximab. In our case, the patient developed Grade 3 diarrhea, prompting the initiation of intravenous prednisolone at 80mg/day in accordance with guidelines. However, symptom improvement was not attained. In situations where symptoms persist beyond three days despite systemic steroid administration, the consideration of adjunctive infliximab use at a dosage of 5mg/kg becomes necessary.
著者関連情報
前の記事 次の記事
feedback
Top